Reduced Risk of Barrett’s Esophagus in Statin Users: Case–Control Study and Meta-Analysis

Beales, Ian; Dearman, Leanne; Vardi, Inna; Loke, Yoon K.

doi:10.1007/s10620-015-3869-4

Cited by 27 publications

(15 citation statements)

References 42 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a systematic review and meta-analysis, age, male gender, smoking, longer BE segment, and lowgrade dysplasia were risk factors for BE progression (31). However, other studies continue to suggest that GERD is the strongest risk factor for BE.…”

Section: Discussionmentioning

confidence: 98%

“…However, other studies continue to suggest that GERD is the strongest risk factor for BE. Moreover, the use of statin alone or in combination with aspirin as well as proton pump inhibitors (PPI) significantly reduced the risk of BE (31,32). In another meta-analysis, infection with Helicobacter pylori (H. pylori) also reduced the risk of BE (33).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The relationship between metabolic syndrome and increased risk of Barrett's esophagus: An Updated systematic review and meta-analysis

Karimian

Salamati

Azami

2020

Preprint

View full text Add to dashboard Cite

Background: The relationship between metabolic syndrome ( MetS) and Barrett's esophagus (BE) is still a challenging issue, and inconsistent results have been reported in different studies. Therefore, this study was conducted to determine the relationship between MetS and BE. Methods : In this study, we followed the MOOSE protocol and the PRISMA guidelines for reporting the results. All study steps were performed independently by two authors. If necessary, the dispute was resolved by consultation with a third author. The search strategy is designed to find published studies. Comprehensive search was done in the following biomedical databases until July 2019: Cochrane Library, PubMed/Medline, Web of Science, Science Direct, EMBASE, Scopus, CINAHL, EBSCO, and Google Scholar search engine. All analyses were performed using Comprehensive Meta-Analysis Software Ver.2, while p-value lower than 0.05 was considered significant. Results : In 14 studies with a sample size of 108416, MetS significantly increased the risk of BE (OR=1.315; 95% CI: 1.110-1.558; P<0.001; Heterogeneity: I 2 = 81.55; P<0.001). Sensitivity analysis by omitting one study showed that overall estimates are still robust. Subgroup analysis was significant for continent (P<0.001) and MetS diagnostic criteria (P=0.043), but was not significant for variables of study type (P=0.899), study setting (P=0.115), control groups (P=0.671) and quality of studies (P=0.603). The Begg (P=0.912) and Egger's (P=0.094) tests were not significant; therefore, the publication bias did not play a role in the results. Conclusion: MetS increases the risk of BE compared to control groups. Future studies should examine whether treatment for metabolic syndrome reduces the risk of BE.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

The relationship between metabolic syndrome and increased risk of Barrett's esophagus: An Updated systematic review and meta-analysis

Karimian

Salamati

Azami

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, other studies continue to suggest that GERD is the strongest risk factor for BE. Moreover, the use of statin alone or in combination with aspirin as well as proton pump inhibitors (PPI) significantly reduced the risk of BE [31,32]. In another meta-analysis, infection with Helicobacter pylori (H. pylori) also reduced the risk of BE [33].…”

Section: Discussionmentioning

confidence: 99%

The relationship between metabolic syndrome and increased risk of Barrett’s esophagus: an updated systematic review and meta-analysis

2020

View full text Add to dashboard Cite

Background: The relationship between metabolic syndrome (MetS) and Barrett's esophagus (BE) is still a challenging issue, and inconsistent results have been reported in different studies. Therefore, this study was conducted to determine the relationship between MetS and BE. Methods: In this study, we followed the MOOSE protocol and results were reported according to the PRISMA guidelines. All study steps were performed independently by two authors. If necessary, the dispute was resolved by consultation with a third author. The search strategy is designed to find published studies. Comprehensive search was done in the following databases until July 2019: Cochrane Library, PubMed/Medline, Web of Science, Science Direct, EMBASE, Scopus, CINAHL, EBSCO, and Google Scholar search engine. All analyses were performed using Comprehensive Meta-Analysis Software Ver.2, while p-value lower than 0.05 was considered significant. Results: In 14 studies with a sample size of 108,416, MetS significantly increased the risk of BE (OR = 1.354; 95% CI: 1.145-1.600; P < 0.001; Heterogeneity: I 2 = 81.95%; P < 0.001). Sensitivity analysis by omitting one study showed that overall estimates are still robust. Subgroup analysis was significant for continent (P < 0.001) and MetS diagnostic criteria (P = 0.043), but was not significant for variables of study type (P = 0.899), study setting (P = 0.115), control groups (P = 0.671) and quality of studies (P = 0.603). The Begg (P = 0.912) and Egger's (P = 0.094) tests were not significant; therefore, the publication bias did not play a role in the results. Conclusion: MetS increases the risk of BE compared to control groups. The results of this study can help health practitioners by identifying a treatable risk factor for the most important risk factor for esophageal carcinoma (ie, BE). Future studies should examine whether treatment for MetS reduces the risk of BE.

show abstract

“…It remains an area of active research whether statins have beneficial anti-cancer effects merely on progression of non-dysplastic BO or whether they are actually associated with a reduction in the development of BO itself. Whilst most of the in vitro studies have examined the effects of statins on various models of Barrett’s oesophagus, recent data including a meta-analysis have reported that statin use is associated with a reduced incidence Barrett’s oesophagus [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma

Thomas

Loke

Beales

2017

J Gastrointest Canc

Self Cite

View full text Add to dashboard Cite

PurposeLaboratory studies have suggested that statins may have useful anti-cancer effects against Barrett’s epithelial cancer lines. A variety of effects have been reported in clinical studies.MethodsWe performed a systematic review and meta-analysis of the association between statin use and the development of oesophageal cancer. Multiple databases were searched for studies reporting the association of statin use and oesophageal cancer. Meta-analysis on the relationship between statin use and cancer incidence was performed.ResultsTwenty publications met eligibility criteria, yielding 22 datasets for meta-analysis. All were observational studies. Population-level studies included 372,206 cancer cases and 6,086,906 controls. Studies examining adenocarcinoma development in Barrett’s oesophagus included 1057 cancers and 17,741 controls. In patients with Barrett’s oesophagus, statin use was associated with a reduced incidence of adenocarcinoma (pooled adjusted odds ratio (OR) 0.59 (95% confidence intervals 0.50–0.68)), with no heterogeneity between 11 studies. Population-based studies demonstrated more heterogeneity but showed that statin use was associated with a lower incidence of both oesophageal adenocarcinoma (OR 0.57 (0.43–0.76)) and all oesophageal cancers (OR 0.82 (0.7–0.88)). Information on statin type, dose, and duration was reported too infrequently for statistical analysis but individual studies showed a tendency to a dose- and duration-dependant decrease in cancer incidence.ConclusionsStatin use is associated with a significantly lower incidence of oesophageal adenocarcinoma. This is seen in both Barrett’s cohorts and general populations. Further studies should focus on drug, dose, and duration and the interaction with other risk and preventative factors.Electronic supplementary materialThe online version of this article (doi:10.1007/s12029-017-9983-0) contains supplementary material, which is available to authorized users.

show abstract

Reduced Risk of Barrett’s Esophagus in Statin Users: Case–Control Study and Meta-Analysis

Cited by 27 publications

References 42 publications

The relationship between metabolic syndrome and increased risk of Barrett's esophagus: An Updated systematic review and meta-analysis

The relationship between metabolic syndrome and increased risk of Barrett's esophagus: An Updated systematic review and meta-analysis

The relationship between metabolic syndrome and increased risk of Barrett’s esophagus: an updated systematic review and meta-analysis

Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma

Contact Info

Product

Resources

About